Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2013

01-03-2013 | Review

Resolution of inflammation as a novel chemopreventive strategy

Authors: Ha-Na Lee, Hye-Kyung Na, Young-Joon Surh

Published in: Seminars in Immunopathology | Issue 2/2013

Login to get access

Abstract

Acute inflammation, a physiologic response to protect cells from microbial infection and other noxious stimuli, is automatically terminated by endogenous anti-inflammatory and pro-resolving mediators to restore homeostatic conditions. However, if timely resolution of inflammation is failed, inflammation persists and can progress to a chronic inflammation which has long been thought as a predisposing factor to carcinogenesis. Excessive and pathologic inflammation causes DNA damage, genomic instability, epigenetic dysregulation, and alteration of intracellular signaling, all of which are involved in neoplastic transformation. To prevent chronic inflammation and resulting inflammation-promoted cancer development, understanding the process that resolves inflammation is essential. Resolution of inflammation is an active coordinated process regulated by distinct anti-inflammatory and pro-resolving endogenous lipid mediators, such as resolvins and lipoxins. The role of pro-inflammatory signaling in carcinogenesis has become more and more evident and well characterized, but the potential role of pro-resolving mediators in cancer prevention remains still elusive. In searching for an efficacious way to prevent chronic inflammation-associated cancer, the pro-resolving signal transduction pathways and their regulators should be unraveled.
Literature
1.
2.
Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439PubMedCrossRef
3.
Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18:3831–3852PubMedCrossRef
4.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef
5.
6.
Radisky DC, Kenny PA, Bissell MJ (2007) Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 101:830–839PubMedCrossRef
7.
Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15:1–9PubMedCrossRef
8.
Stevens DL (1995) Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial-infections to toxic shock syndrome. Clin Infect Dis 21:977–980PubMedCrossRef
9.
Rodriguez-Vita J, Lawrence T (2010) The resolution of inflammation and cancer. Cytokine Growth Factor Rev 21:61–65PubMedCrossRef
10.
Wilting J, Becker J, Buttler K, Weich HA (2009) Lymphatics and inflammation. Curr Med Chem 16:4581–4592PubMedCrossRef
11.
Huynh MLN, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta 1 secretion and the resolution of inflammation. J Clin Invest 109:41–50PubMed
12.
13.
Samuelsson B (1983) From studies of biochemical-mechanism to novel biological mediators—prostaglandin endoperoxides, thromboxanes, and leukotrienes. Angew Chem Int Edit 22:805–815CrossRef
14.
Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc 31:986–1000CrossRef
15.
Oshima H, Hioki K, Popivanova BK, Oguma K, Van Rooijen N, Ishikawa TO, Oshima M (2011) Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140:596–607.e7PubMedCrossRef
16.
Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100:9044–9049PubMedCrossRef
17.
McCoy JM, Wicks JR, Audoly LP (2002) The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651–658PubMed
18.
Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, Koller BH (1999) Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 163:6810–6819PubMed
19.
Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197PubMedCrossRef
20.
Lawrence T, Willoughby DA, Gilroy DW (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2:787–795PubMedCrossRef
21.
Il Lee S, Zuo XS, Shureiqi I (2011) 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev 30:481–491PubMedCrossRef
22.
Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111:5922–5943PubMedCrossRef
23.
Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447:869–874PubMedCrossRef
24.
Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102:7671–7676PubMedCrossRef
25.
Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE (2006) RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20:401–403PubMed
26.
Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–619PubMedCrossRef
27.
Spite M, Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation impact of aspirin and statins. Circ Res 107:1170–1184PubMedCrossRef
28.
Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN (2003) Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171:3936–3940PubMed
29.
Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K (2002) 15-Deoxy-Δ12,14-prostaglandin J2—a prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277:10459–10466PubMedCrossRef
30.
Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, Kim DD (2011) 15-Deoxy-Δ12,14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem Pharmacol 82:1335–1351PubMedCrossRef
31.
Lee YC (2004) The role of PTEN in allergic inflammation. Arch Immunol Ther Exp 52:250–254
32.
Croker BA, Kiu H, Pellegrini M, Toe J, Preston S, Metcalf D, O’Donnell JA, Cengia LH, McArthur K, Nicola NA, Alexander WS, Roberts AW (2012) IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol 90:124–129PubMedCrossRef
33.
Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKK alpha limits macrophage NF-kappa B activation and contributes to the resolution of inflammation. Nature 434:1138–1143PubMedCrossRef
34.
Balode L, Strazda G, Jurka N, Kopeika U, Kislina A, Bukovskis M, Beinare M, Gardjusina V, Taivans I (2012) Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease. Medicina (Kaunas) 48:292–298
35.
Wu WKK, Sung JJY, Lee CW, Yu J, Cho CH (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 295:7–16PubMedCrossRef
36.
Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386PubMedCrossRef
37.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504–1510PubMedCrossRef
38.
Sheng HM, Shao JY, Washington MK, DuBois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075–18081PubMedCrossRef
39.
Fukuda R, Kelly B, Semenza GL (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330–2334PubMed
40.
Sakai H, Suzuki T, Takahashi Y, Ukai M, Tauchi K, Fujii T, Horikawa N, Minamimura T, Tabuchi Y, Morii M, Tsukada K, Takeguchi N (2006) Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett 580:3368–3374PubMedCrossRef
41.
Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574–4577PubMed
42.
Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T (2002) Gene transfer of thromboxane A2 synthase and prostaglandin I2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63–66PubMed
43.
Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, Lundholm K (2007) Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 46:1107–1112PubMedCrossRef
44.
Cutler NS, Graves-Deal R, LaFleur BJ, Gao ZQ, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ (2003) Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63:1748–1751PubMed
45.
Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62:28–32PubMed
46.
Qualtrough D, Kaidi A, Chell S, Jabbour HN, Williams AC, Paraskeva C (2007) Prostaglandin F2α stimulates motility and invasion in colorectal tumor cells. Int J Cancer 121:734–740PubMedCrossRef
47.
48.
Morimoto K, Janssen WJ, Terada M (2012) Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med 106:1800–1803PubMedCrossRef
49.
Imanishi T, Akasaka T (2013) Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Des (in press)
50.
Herlong JL, Scott TR (2006) Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 102:121–131PubMedCrossRef
51.
Ragolia L, Palaia T, Hall CE, Klein J, Buyud A (2010) Diminished lipocalin-type prostaglandin D2 synthase expression in human lung tumors. Lung Cancer 70:103–109PubMedCrossRef
52.
Payne CA, Maleki S, Messina M, O’Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL (2008) Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther 7:3420–3428PubMedCrossRef
53.
Eichele K, Ramer R, Hinz B (2008) Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 27:3032–3044PubMedCrossRef
54.
Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M, Momotani E, Urade Y, Ozaki H (2011) Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 108:19802–19807PubMedCrossRef
55.
Park JM, Kanaoka Y, Eguchi N, Aritake K, Grujic S, Materi AM, Buslon VS, Tippin BL, Kwong AM, Salido E, French SW, Urade Y, Lin HJ (2007) Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res 67:881–889PubMedCrossRef
56.
Janakiram NB, Rao CV (2009) Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 9:565–579PubMedCrossRef
57.
Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussali MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE (1999) Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20:1985–1995
58.
Kamitani H, Geller M, Eling T (1998) Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273:21569–21577PubMedCrossRef
59.
Kim JS, Baek SJ, Bottone FG, Sali T, Eling TE (2005) Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol Cancer Res 3:511–517PubMedCrossRef
60.
Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H (2007) Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 51:520–527PubMedCrossRef
61.
Jiang WG, Douglas-Jones A, Mansel RE (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent 69:275–281CrossRef
62.
Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, Arita M, Azuma T, Yoshida M (2010) Lipoxin A4 reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther 332:541–548PubMedCrossRef
63.
Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 99:13266–13271PubMedCrossRef
64.
Hachicha M, Pouliot M, Petasis NA, Serhan CN (1999) Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1 alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189:1923–1929PubMedCrossRef
65.
Hao H, Liu M, Wu P, Cai L, Tang K, Yi P, Li YS, Chen Y, Ye DY (2011) Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 309:85–94PubMedCrossRef
66.
Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T (2010) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 16:87–95PubMedCrossRef
67.
Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, Kang JX (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 28:1991–1995PubMedCrossRef
68.
Harris SG, Smith RS, Phipps RP (2002) 15-Deoxy-Δ12,14-PGJ2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 168:1372–1379PubMed
69.
Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Yamamoto N, Sugimoto K, Murata K, Nakano T (2003) 15-Deoxy-Δ12,14-PGJ2 regulates apoptosis induction and nuclear factor-kappa B activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 83:1529–1539PubMedCrossRef
Metadata
Title
Resolution of inflammation as a novel chemopreventive strategy
Authors
Ha-Na Lee
Hye-Kyung Na
Young-Joon Surh
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2013
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-013-0363-y

Other articles of this Issue 2/2013

Seminars in Immunopathology 2/2013 Go to the issue

Review

Multifaceted roles of PGE2 in inflammation and cancer

Review

Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis

Introduction

Introduction for inflammation and cancer

Review

Inflammation and colorectal cancer: colitis-associated neoplasia

Review

The role of PGE2-associated inflammatory responses in gastric cancer development

Review

Mast cells and inflammation-associated colorectal carcinogenesis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits